Gilead’s Darusentan, A Potential Blockbuster, Posts Positive Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts pleasantly surprised at both efficacy and safety data for the novel candidate as add-on treatment for resistant hypertension.